Literature DB >> 19643412

Atherogenic lipoprotein phenotype and LDL size and subclasses in drug-naïve patients with early rheumatoid arthritis.

Manfredi Rizzo1, Giatgen A Spinas, Mustafa Cesur, Zeynep Ozbalkan, Giovam Battista Rini, Kaspar Berneis.   

Abstract

OBJECTIVE: Subjects with rheumatoid arthritis (RA) have increased cardiovascular risk and may show atherogenic forms of dyslipidemia. The present study investigated whether patients with early RA, beyond alterations in plasma lipids, also show lower LDL size and altered LDL subclass distribution. DESIGN AND METHODS: We identified 25 subjects with RA (47+/-8 years, body mass index (BMI) 25+/-4kg/m(2)) by the American College of Rheumatology diagnostic criteria, with a disease durations <1 year and no prior treatment against it. In patients and 22 healthy subjects matched for age and BMI (controls) we measured plasma lipids and LDL size and subclasses by gradient gel electrophoresis.
RESULTS: As compared to controls RA patients had higher plasma triglycerides (1.8+/-0.5 vs. 1.0+/-0.5mmol/L, p<0.0001) and lower HDL-cholesterol concentrations (1.2+/-0.2 vs. 1.4+/-0.2mmol/L, p=0.0027), while total- and LDL-cholesterol concentrations were similar. LDL particle size was lower in RA patients than controls (264+/-7 vs. 281+/-9A, p<0.0001), due to less LDL-I (31+/-6 vs. 38+/-7%, p=0.0004) and LDL-IIA (14+/-3 vs. 16+/-3%, p=0.0182), and more LDL-IIIB (7+/-1 vs. 5+/-1%), -IVA (11+/-2 vs. 8+/-2%) and -IVB particles (12+/-2 vs. 9+/-2%,) (p<0.0001 for all). Further, about 1/3 of patients showed the complete "atherogenic-lipoprotein-phenotype" (e.g. the concomitant presence of high triglycerides, low HDL-cholesterol and elevated small, dense LDL).
CONCLUSIONS: Beyond plasma lipids, increased levels of small, dense LDL seems to be common in drug-naïve patients with early RA. Yet, whether these findings affect the atherogenic process and the clinical endpoints in these subjects remains to be determined by future prospective studies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19643412     DOI: 10.1016/j.atherosclerosis.2009.07.015

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  22 in total

1.  Serum Lipid Alterations in Early Rheumatoid Arthritis Patients on Disease Modifying Anti Rheumatoid Therapy.

Authors:  Sana Parveen; Rachel Jacob; Liza Rajasekhar; C Srinivasa; Iyyapu Krishna Mohan
Journal:  Indian J Clin Biochem       Date:  2016-04-22

2.  Management of cardiovascular risk in patients with rheumatoid arthritis: evidence and expert opinion.

Authors:  Inge A M van den Oever; Alper M van Sijl; Michael T Nurmohamed
Journal:  Ther Adv Musculoskelet Dis       Date:  2013-08       Impact factor: 5.346

3.  Association of rheumatoid arthritis disease activity and antibodies to periodontal bacteria with serum lipoprotein profile in drug naive patients.

Authors:  Aulikki Kononoff; Pia Elfving; Pirkko Pussinen; Sohvi Hörkkö; Hannu Kautiainen; Leena Arstila; Leena Laasonen; Elina Savolainen; Helena Niinisalo; Jarno Rutanen; Olga Marjoniemi; Mari Hämäläinen; Katriina Vuolteenaho; Eeva Moilanen; Oili Kaipiainen-Seppänen
Journal:  Ann Med       Date:  2020-02-10       Impact factor: 4.709

4.  Epicardial adipose tissue thickness, flow-mediated dilatation of the brachial artery, and carotid intima-media thickness: Associations in rheumatoid arthritis patients.

Authors:  A Temiz; F Gökmen; E Gazi; A Akbal; A Barutçu; A Bekler; B Altun; Y Z Tan; F Güneş; H Şen
Journal:  Herz       Date:  2014-08-21       Impact factor: 1.443

5.  Anti-arthritic effect of GN1, a novel synthetic analog of glucosamine, in the collagen-induced arthritis model in rats.

Authors:  Huma Jawed; Shazia Anjum; Shahid I Awan; Shabana U Simjee
Journal:  Inflamm Res       Date:  2011-08-27       Impact factor: 4.575

Review 6.  Rheumatoid arthritis and metabolic syndrome.

Authors:  György Kerekes; Michael T Nurmohamed; Miguel A González-Gay; Ildikó Seres; György Paragh; Zsófia Kardos; Zsuzsa Baráth; László Tamási; Pál Soltész; Zoltán Szekanecz
Journal:  Nat Rev Rheumatol       Date:  2014-08-05       Impact factor: 20.543

Review 7.  Inflammation, lipid metabolism and cardiovascular risk in rheumatoid arthritis: A qualitative relationship?

Authors:  Carmen García-Gómez; Maria Bianchi; Diana de la Fuente; Lina Badimon; Teresa Padró; Emili Corbella; Xavier Pintó
Journal:  World J Orthop       Date:  2014-07-18

Review 8.  Untying the correlation between apolipoproteins and rheumatoid arthritis.

Authors:  Rashita Makkar; Tapan Behl; Arun Kumar; Md Sahab Uddin; Simona Bungau
Journal:  Inflamm Res       Date:  2020-10-14       Impact factor: 4.575

9.  Changes in lipoproteins associated with methotrexate or combination therapy in early rheumatoid arthritis: results from the treatment of early rheumatoid arthritis trial.

Authors:  Iris Navarro-Millán; Christina Charles-Schoeman; Shuo Yang; Joan M Bathon; S Louis Bridges; Lang Chen; Stacey S Cofield; Louis J Dell'Italia; Larry W Moreland; James R O'Dell; Harold E Paulus; Jeffrey R Curtis
Journal:  Arthritis Rheum       Date:  2013-06

Review 10.  Newest clinical trial results with antitumor necrosis factor and nonantitumor necrosis factor biologics for rheumatoid arthritis.

Authors:  Iris Navarro-Millán; Jeffrey R Curtis
Journal:  Curr Opin Rheumatol       Date:  2013-05       Impact factor: 5.006

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.